HK Stock Market Move | JF SMARTINVEST(09636) surged more than 15%, the company fully benefits from active market trading, AI empowerment, and platformization opening up growth opportunities.
Jiufang Intelligent Investment Holdings (09636) surged over 15%, as of the time of writing, up 15.25% to HK$29.48, with a turnover of HK$157 million.
JF SMARTINVEST (09636) rose more than 15%, reaching 15.25% at the time of writing, to HK$29.48, with a turnover of HK$157 million.
On the news front, data disclosed earlier by the Shanghai Stock Exchange showed that the number of new A-share accounts opened in May 2026 was 2.7653 million, up 77.76% year-on-year and 11% month-on-month, stabilizing the significant decline in April. Of these, 2.7551 million were opened by individual investors and 10,200 by institutional investors. In addition, JF SMARTINVEST continued its high-frequency repurchase pace in June. As of June 11, it had made 7 repurchases for the month, buying approximately 846,800 shares totaling over HK$22.21 million.
Guosheng believes that JF SMARTINVEST, as a leading financial information service provider for investment advisors, with outstanding valuation elasticity and steady growth, is expected to benefit fully from active market trading, AI empowerment, and platformization opening up growth space. Since 2025, it has been exploring new boundaries in business: launching new AI products such as "Nine Xun" and "Nine Zhi Yan" to accelerate the application of AI in investment advisory scenarios; strategically investing in the Hong Kong licensed virtual asset trading platform EX.IO to explore the Web3 and digital asset field.
Related Articles

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

SEACON (02409) subsidiary enters into a vessel time charter arrangement with Zhejiang Shipping (Singapore)
RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

SEACON (02409) subsidiary enters into a vessel time charter arrangement with Zhejiang Shipping (Singapore)

RECOMMEND





